Tenax Therapeutics: A Binary Bet With Heavy Downside Likely [Seeking Alpha]
Tenax Therapeutics, Inc. (TENX)
Last tenax therapeutics, inc. earnings: 11/14 04:31 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.tenaxthera.com
Company Research
Source: Seeking Alpha
Despite optimistic assumptions—50% POS, 100k Target Pop., 15% Peak Share, and $35k Net Price—risk-adjusted NPV remains well below TENX's current valuation. LEVEL's primary endpoint (6MWD) is noisy, with significant IV-to-oral translation risk and a much narrower, specialist-driven TAM than prevalence implies. I initiate TENX with a 'Sell' rating, citing negative risk/reward skew even under bullish scenarios and high volatility unanchored to fundamentals. Vakidzasi/iStock via Getty Images Tenax Therapeutics Overview Tenax Therapeutics ( TENX ) is a clean story, which will make it pretty easy to model. Tenax is actively advancing just one product (TNX-103 or oral levosimendan) in one indication (PH-HFpEF). Below, I explain This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it
Show less
Read more
Impact Snapshot
Event Time:
TENX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TENX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TENX alerts
High impacting Tenax Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TENX
News
- Tenax Therapeutics (TENX) is now covered by Cantor Fitzgerald. They set an "overweight" rating and a $35.00 price target on the stock.MarketBeat
- Tenax Therapeutics (TENX) had its price target raised by Guggenheim from $25.00 to $34.00. They now have a "buy" rating on the stock.MarketBeat
- Tenax Therapeutics (TENX) was upgraded by Lifesci Capital to "strong-buy".MarketBeat
- Tenax Therapeutics (TENX) had its "outperform" rating reaffirmed by William Blair.MarketBeat
- Tenax Therapeutics GAAP EPS of -$0.38 beats by $0.03 [Seeking Alpha]Seeking Alpha
TENX
Sec Filings
- 3/10/26 - Form SCHEDULE
- 3/10/26 - Form 10-K
- 3/10/26 - Form 8-K
- TENX's page on the SEC website